Atezolizumab in "Real World" Patients: Do Phase 3b Trials Help Bridge the Gap Between Efficacy and Effectiveness?

Eur Urol. 2019 Jul;76(1):82-83. doi: 10.1016/j.eururo.2019.04.004. Epub 2019 Apr 19.

Authors

Vaibhav G Patel¹, Matthew D Galsky²

Affiliations

¹ Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: vaibhav.patel@mountsinai.org.
² Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 31006493
DOI: 10.1016/j.eururo.2019.04.004

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Carcinoma*
Humans
Lung Neoplasms*
Urinary Tract*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
atezolizumab